Skip to main navigation

Skip to content

Customer Service: 866-788-9007

PHYSICIAN LOGIN | CRF LOGIN

ORDER TEST

Company
Products
Research & Development
Investors
Scientific Publications
Resources

November 11, 2019 Castle Biosciences Reports Third Quarter 2019 Results

Email Alerts

Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
End of the Day SEC Filing
Event
News

Email

Latest News

Castle Biosciences Reports Third Quarter 2019 Results November 11, 2019
Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk October 31, 2019
Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting October 29, 2019
Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019 October 28, 2019
Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis October 28, 2019

Site - Investor Tools

Print Page

RSS Feeds

Email Alerts

Investor Contact

Investor Contact

Search

Connect with Us

Company

About Us
History
Leadership
- Executive Management
- Board of Directors
Licenses
Careers
Contact Us

Products

Cutaneous Melanoma
- DecisionDx-Melanoma
- DecisionDx-CMSeq
Uveal Melanoma

Research & Development

Our Approach
Tests in Development
Cutaneous Squamous Cell Carcinoma
Suspicious Pigmented Lesions

Latest News & Publications

Press Releases
Scientific Publications
Email Alerts

Resources

Healthcare Professionals
Patients

Copyright © 2019 Castle Biosciences, Inc. | All Rights Reserved

Privacy Policy
Terms of Use
Contact Us

7ads6x98y